Multiply Labs, a developer of autonomous manufacturing technology for advanced therapies, entered an agreement with AstraZeneca to evaluate the potential for applying GMP (Good Manufacturing Practices)-ready robotic systems to commercial-scale cell therapy manufacturing.  

The collaboration will focus on end-to-end robotic automation of industry-standard instruments used in cell therapy production using Multiply Labs’ robotic biomanufacturing system. The goal is to enable scalable, high-throughput manufacturing while maintaining the rigorous quality and regulatory standards required for clinical and commercial use.

Multiply Labs’ newest systems use four robotic arms operating in parallel to run a broad range of cell therapy manufacturing instruments already in use by the industry. According to the company, this architecture minimizes the need for process modifications while maximizing output in existing facilities, targeting higher productivity.

“Cell therapies are among the most promising, yet complex medicines being developed today,” says Fred Parietti, PhD, CEO of Multiply Labs. “Our mission is to make these therapies more widely available by increasing manufacturing efficiency and scale. This agreement with AstraZeneca allows us to evaluate our multi-arm robotic clusters in a setting where we can combine some of the world’s best scientific and clinical expertise with our robotic platform to build the next generation of high-throughput, GMP-ready cell therapy manufacturing.”